C
Christopher T. Harbison
Researcher at Bristol-Myers Squibb
Publications - 64
Citations - 17793
Christopher T. Harbison is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Nivolumab & Cetuximab. The author has an hindex of 32, co-authored 64 publications receiving 15167 citations. Previous affiliations of Christopher T. Harbison include University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
Julie R. Brahmer,Karen L. Reckamp,Paul Baas,Lucio Crinò,Wilfried Eberhardt,Elena Poddubskaya,Scott J. Antonia,Adam Pluzanski,Everett E. Vokes,Esther Holgado,David M. Waterhouse,Neal Ready,Justin F. Gainor,Osvaldo Arén Frontera,Libor Havel,Martin Steins,Marina Chiara Garassino,Joachim G.J.V. Aerts,Manuel Domine,Luis Paz-Ares,Martin Reck,Christine Baudelet,Christopher T. Harbison,Brian Lestini,David R. Spigel +24 more
TL;DR: Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level.
Journal ArticleDOI
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder,Vladimir Makarov,Taha Merghoub,Jianda Yuan,Jesse M. Zaretsky,Alexis Desrichard,Logan A. Walsh,Michael A. Postow,Phillip Wong,Teresa S. Ho,Travis J. Hollmann,Cameron Bruggeman,Kasthuri Kannan,Yanyun Li,Ceyhan Elipenahli,Cailian Liu,Christopher T. Harbison,Lisu Wang,Antoni Ribas,Jedd D. Wolchok,Jedd D. Wolchok,Timothy A. Chan +21 more
TL;DR: In this paper, the authors provide clarification and correction to their article "Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma" (Dec. 4, 2014, issue).
Journal ArticleDOI
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A. Rizvi,Julien Mazieres,David Planchard,Thomas E. Stinchcombe,Grace K. Dy,Scott J. Antonia,Leora Horn,Hervé Lena,Elisa Minenza,Bertrand Mennecier,Gregory A. Otterson,Luis T. Campos,David R. Gandara,Benjamin Levy,Suresh G. Nair Md,Gérard Zalcman,Jürgen Wolf,Pierre Jean Souquet,Editta Baldini,Federico Cappuzzo,Christos Chouaid,Afshin Dowlati,Rachel E. Sanborn,Ariel Lopez-Chavez,Christian Grohe,Rudolf M. Huber,Christopher T. Harbison,Christine Baudelet,Brian Lestini,Suresh S. Ramalingam +29 more
TL;DR: Nivolumab has clinically meaningful activity and a manageable safety profile in previously treated patients with advanced, refractory, squamous non-small cell lung cancer and these data support the assessment of nivolumsab in randomised, controlled, phase 3 studies of first-line and second-line treatment.
Journal ArticleDOI
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
Shirin Khambata-Ford,Christopher R. Garrett,Neal J. Meropol,Mark Basik,Christopher T. Harbison,Shujian Wu,Tai W. Wong,Xin Huang,Chris H. Takimoto,Andrew K. Godwin,Benjamin R. Tan,Smitha S. Krishnamurthi,Howard A. Burris,Elizabeth Poplin,Manuel Hidalgo,José Baselga,Edwin A. Clark,David J. Mauro +17 more
TL;DR: Gene expression profiles showed that patients with tumors that express high levels of the EGFR ligands epiregulin and amphireGulin and patients with wild-type K-ras are more likely to have disease control on cetuximab treatment.
Journal ArticleDOI
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J. Antonia,Jose A. Lopez-Martin,Johanna C. Bendell,Patrick A. Ott,Matthew H. Taylor,Joseph Paul Eder,Dirk Jäger,M. Catherine Pietanza,Dung T. Le,Filippo de Braud,Michael A. Morse,Paolo A. Ascierto,Leora Horn,Asim Amin,Rathi N. Pillai,Jeffry Evans,Ian Chau,Petri Bono,Akin Atmaca,Padmanee Sharma,Christopher T. Harbison,Chen Sheng Lin,Olaf Christensen,Emiliano Calvo +23 more
TL;DR: An objective response was achieved in ten (10%) of 98 patients receiving nivolumab 3 mg/kg, one (33%) of three patients receivingnivolUMab 1mg/kg plus ipilimumab 1 mg /kg, and 14 (23%) of 61 receiving n ivolumAB 1 mg/ kg plus ipILimumab 3mg/ kg, and ten (19%) of 54 receiving nvolum ab 3 mg / kg plusipilimum